NO309458B1 - Hepatitisvaksiner som inneholder 3-O-deacylert monofosforyl- lipid A og anvendelse derav - Google Patents
Hepatitisvaksiner som inneholder 3-O-deacylert monofosforyl- lipid A og anvendelse derav Download PDFInfo
- Publication number
- NO309458B1 NO309458B1 NO943571A NO943571A NO309458B1 NO 309458 B1 NO309458 B1 NO 309458B1 NO 943571 A NO943571 A NO 943571A NO 943571 A NO943571 A NO 943571A NO 309458 B1 NO309458 B1 NO 309458B1
- Authority
- NO
- Norway
- Prior art keywords
- hepatitis
- antigen
- hbsag
- vaccine preparation
- mpl
- Prior art date
Links
- 229940035032 monophosphoryl lipid a Drugs 0.000 title claims abstract description 10
- 229960002520 hepatitis vaccine Drugs 0.000 title description 7
- 229960005486 vaccine Drugs 0.000 claims abstract description 65
- 239000000427 antigen Substances 0.000 claims abstract description 44
- 102000036639 antigens Human genes 0.000 claims abstract description 44
- 108091007433 antigens Proteins 0.000 claims abstract description 44
- 208000006454 hepatitis Diseases 0.000 claims abstract description 25
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 25
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 208000015181 infectious disease Diseases 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 229940037003 alum Drugs 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims description 45
- 208000005252 hepatitis A Diseases 0.000 claims description 10
- 229940029583 inactivated polio vaccine Drugs 0.000 claims description 6
- 241000700721 Hepatitis B virus Species 0.000 claims description 5
- 201000005702 Pertussis Diseases 0.000 claims description 5
- 230000004224 protection Effects 0.000 claims description 5
- 206010043376 Tetanus Diseases 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 206010013023 diphtheria Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 102100031673 Corneodesmosin Human genes 0.000 claims description 3
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000007764 o/w emulsion Substances 0.000 claims description 3
- 101710139375 Corneodesmosin Proteins 0.000 claims description 2
- 241000606768 Haemophilus influenzae Species 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims description 2
- 208000000474 Poliomyelitis Diseases 0.000 claims description 2
- 101710137302 Surface antigen S Proteins 0.000 claims description 2
- 239000011246 composite particle Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 208000005331 Hepatitis D Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 201000010284 hepatitis E Diseases 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 25
- 230000000694 effects Effects 0.000 description 19
- 230000004044 response Effects 0.000 description 19
- 241000709721 Hepatovirus A Species 0.000 description 14
- 230000028327 secretion Effects 0.000 description 14
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 13
- 230000006698 induction Effects 0.000 description 13
- 239000002245 particle Substances 0.000 description 13
- 230000003053 immunization Effects 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 230000024932 T cell mediated immunity Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 229940124884 Engerix-B Drugs 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- 230000005875 antibody response Effects 0.000 description 7
- 229940124914 Havrix Drugs 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 6
- 210000000447 Th1 cell Anatomy 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 5
- 230000004727 humoral immunity Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010019799 Hepatitis viral Diseases 0.000 description 4
- 229940001442 combination vaccine Drugs 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940021747 therapeutic vaccine Drugs 0.000 description 4
- 201000001862 viral hepatitis Diseases 0.000 description 4
- 241000711549 Hepacivirus C Species 0.000 description 3
- 241000724675 Hepatitis E virus Species 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229940124724 hepatitis-A vaccine Drugs 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 206010018072 General signs and symptoms Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- -1 Tween 80 Chemical compound 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007689 endotoxicity Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929206789A GB9206789D0 (en) | 1992-03-27 | 1992-03-27 | Vaccine |
| GB929206786A GB9206786D0 (en) | 1992-03-27 | 1992-03-27 | Vaccine |
| GB929206797A GB9206797D0 (en) | 1992-03-27 | 1992-03-27 | Vaccine |
| GB929206788A GB9206788D0 (en) | 1992-03-27 | 1992-03-27 | Vaccine |
| PCT/EP1993/000712 WO1993019780A1 (en) | 1992-03-27 | 1993-03-24 | Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO943571D0 NO943571D0 (no) | 1994-09-26 |
| NO943571L NO943571L (no) | 1994-11-14 |
| NO309458B1 true NO309458B1 (no) | 2001-02-05 |
Family
ID=27450853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO943571A NO309458B1 (no) | 1992-03-27 | 1994-09-26 | Hepatitisvaksiner som inneholder 3-O-deacylert monofosforyl- lipid A og anvendelse derav |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP0633784B2 (fi) |
| JP (1) | JP3470719B2 (fi) |
| KR (1) | KR100270134B1 (fi) |
| CN (1) | CN1072963C (fi) |
| AP (1) | AP570A (fi) |
| AT (1) | ATE146678T1 (fi) |
| AU (4) | AU3751693A (fi) |
| CA (1) | CA2132833C (fi) |
| CZ (1) | CZ283424B6 (fi) |
| DE (1) | DE69306940T3 (fi) |
| DK (1) | DK0633784T4 (fi) |
| ES (1) | ES2098029T5 (fi) |
| FI (1) | FI110843B (fi) |
| GR (1) | GR3022174T3 (fi) |
| HK (1) | HK1003218A1 (fi) |
| HU (1) | HU221253B1 (fi) |
| IL (1) | IL105161A (fi) |
| MA (1) | MA22842A1 (fi) |
| MY (1) | MY111880A (fi) |
| NO (1) | NO309458B1 (fi) |
| NZ (1) | NZ249868A (fi) |
| RU (1) | RU2121849C1 (fi) |
| SA (1) | SA93130573B1 (fi) |
| SG (1) | SG48375A1 (fi) |
| SI (1) | SI9300149B (fi) |
| SK (1) | SK280160B6 (fi) |
| UA (1) | UA44688C2 (fi) |
| WO (1) | WO1993019780A1 (fi) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9105992D0 (en) * | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
| CN1087176C (zh) * | 1993-03-23 | 2002-07-10 | 史密斯克莱·比奇曼生物公司 | 含有3－o脱酰基单磷酰脂a的疫苗制剂 |
| US6488934B1 (en) | 1995-02-25 | 2002-12-03 | Smithkline Beecham Biologicals S.A. | Hepatitis B vaccine |
| GB9503863D0 (en) * | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
| GB9513261D0 (en) * | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| PL343429A1 (en) * | 1998-03-09 | 2001-08-13 | Smithkline Beecham Biolog | Combined vaccine compositions |
| US6306404B1 (en) | 1998-07-14 | 2001-10-23 | American Cyanamid Company | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
| EP2266604A3 (en) | 1998-10-16 | 2011-05-11 | GlaxoSmithKline Biologicals S.A. | Adjuvant systems and vaccines |
| GB9822714D0 (en) * | 1998-10-16 | 1998-12-09 | Smithkline Beecham Sa | Vaccines |
| FI108150B (fi) | 1999-02-15 | 2001-11-30 | Sulzer Pumpen Ag | Menetelmä ja laitteisto massan käsittelemiseksi |
| US6635261B2 (en) | 1999-07-13 | 2003-10-21 | Wyeth Holdings Corporation | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
| GB9921147D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| US20080085289A1 (en) | 2004-09-22 | 2008-04-10 | Cindy Castado | Immunogenic Composition |
| KR20070116650A (ko) | 2005-03-23 | 2007-12-10 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 조성물 |
| CN102755645A (zh) | 2005-11-04 | 2012-10-31 | 诺华疫苗和诊断有限公司 | 佐剂配制的包含细胞因子诱导剂的流感疫苗 |
| ES2377884T3 (es) | 2005-11-04 | 2012-04-02 | Novartis Vaccines And Diagnostics S.R.L. | Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores |
| JP2009514838A (ja) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 細胞培養物において増殖されたインフルエンザウイルスから調製された非ビリオン抗原を含むアジュバントワクチン |
| AU2006310163B2 (en) | 2005-11-04 | 2011-09-15 | Seqirus UK Limited | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| CA2808919C (en) | 2005-12-22 | 2016-04-19 | Glaxosmithkline Biologicals S.A. | Streptococcus pneumoniae capsular saccharide vaccine |
| DK2478916T3 (da) | 2006-01-27 | 2020-06-15 | Seqirus Uk Ltd | Influenzavacciner indeholdende hæmagglutinin og matrixproteiner |
| ES2376492T3 (es) | 2006-03-23 | 2012-03-14 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores. |
| CA2646349A1 (en) | 2006-03-24 | 2007-10-04 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Storage of influenza vaccines without refrigeration |
| AU2007233705B2 (en) | 2006-03-30 | 2010-12-23 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| US20100015168A1 (en) | 2006-06-09 | 2010-01-21 | Novartis Ag | Immunogenic compositions for streptococcus agalactiae |
| WO2008009309A1 (en) | 2006-07-17 | 2008-01-24 | Glaxosmithkline Biologicals S.A. | Influenza vaccine |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| ES2694805T7 (es) | 2006-09-11 | 2021-10-21 | Seqirus Uk Ltd | Fabricación de vacunas contra virus de la gripe sin usar huevos |
| SG177141A1 (en) | 2006-12-06 | 2012-01-30 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
| PE20090146A1 (es) | 2007-04-20 | 2009-03-23 | Glaxosmithkline Biolog Sa | Composicion inmunogenica contra el virus influenza |
| DK2167121T3 (en) | 2007-06-26 | 2015-11-23 | Glaxosmithkline Biolog Sa | A vaccine comprising Streptococcus pneumoniae kapselpolysaccharidkonjugater |
| EP2185191B1 (en) | 2007-06-27 | 2012-09-12 | Novartis AG | Low-additive influenza vaccines |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| WO2009081172A1 (en) | 2007-12-24 | 2009-07-02 | Novartis Ag | Assays for adsorbed influenza vaccines |
| WO2010099580A1 (en) | 2009-03-05 | 2010-09-10 | Jenny Colleen Mccloskey | Treatment of infection |
| ES2918381T3 (es) | 2009-07-15 | 2022-07-15 | Glaxosmithkline Biologicals Sa | Composiciones de proteína F de VRS y métodos para producir las mismas |
| GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| CN103282375B (zh) | 2010-12-02 | 2017-01-11 | 比奥诺尔免疫有限公司 | 肽支架设计 |
| MX346475B (es) | 2011-01-06 | 2017-03-22 | Bionor Immuno As | Peptidos inmunogenicos monomericos y multimericos. |
| PT2667892T (pt) | 2011-01-26 | 2019-06-07 | Glaxosmithkline Biologicals Sa | Regime de imunização contra o vsr |
| PT2707385T (pt) | 2011-05-13 | 2017-12-19 | Glaxosmithkline Biologicals Sa | Antigénios de f de rsv pré-fusão |
| MX2014014683A (es) | 2012-06-06 | 2015-02-24 | Bionor Immuno As | Peptidos derivados de proteinas virales para usarse como inmunogenos y reactivos de dosificacion. |
| KR20180035807A (ko) | 2015-06-26 | 2018-04-06 | 세퀴러스 유케이 리미티드 | 항원적으로 매치된 인플루엔자 백신 |
| US20230109142A1 (en) | 2020-02-14 | 2023-04-06 | Immunor As | Corona virus vaccine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3584866D1 (de) * | 1984-09-12 | 1992-01-23 | Chiron Corp | Hybridpartikel-immunogene. |
| HU220204B (hu) * | 1987-11-18 | 2001-11-28 | Chiron Corp. | HCV polipeptidek és HCV polinukleotidok, ilyen polinukleotidokat tartalmazó vektorok és ezekkel transzformált gazdasejtek, valamint HCV fertőzés kimutatására szolgáló diagnosztikumok és immunvizsgálati készlet |
| WO1989012641A1 (en) * | 1988-06-17 | 1989-12-28 | Genelabs Incorporated | Enterically transmitted non-a/non-b hepatitis viral agent |
| US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| SG48175A1 (en) * | 1989-07-25 | 1998-04-17 | Smithkline Beecham Biolog | Novel antigens and method for their preparation |
| WO1991004262A1 (en) * | 1989-09-15 | 1991-04-04 | National Institute Of Health Of Japan | New hcv isolates |
| IL97985A0 (en) * | 1990-05-07 | 1992-06-21 | North American Vaccine Inc | Improved vaccine compositions |
| AU9052091A (en) * | 1990-12-20 | 1992-07-22 | Smithkline Beecham Biologicals (Sa) | Vaccines based on hepatitis b surface antigen |
-
1993
- 1993-03-23 MY MYPI93000533A patent/MY111880A/en unknown
- 1993-03-23 MA MA23137A patent/MA22842A1/fr unknown
- 1993-03-24 JP JP51704693A patent/JP3470719B2/ja not_active Expired - Lifetime
- 1993-03-24 NZ NZ249868A patent/NZ249868A/en not_active IP Right Cessation
- 1993-03-24 AT AT93906601T patent/ATE146678T1/de active
- 1993-03-24 AU AU37516/93A patent/AU3751693A/en not_active Abandoned
- 1993-03-24 EP EP93906601A patent/EP0633784B2/en not_active Expired - Lifetime
- 1993-03-24 UA UA94105947A patent/UA44688C2/uk unknown
- 1993-03-24 ES ES93906601T patent/ES2098029T5/es not_active Expired - Lifetime
- 1993-03-24 SG SG1996009183A patent/SG48375A1/en unknown
- 1993-03-24 RU RU94042386A patent/RU2121849C1/ru active
- 1993-03-24 KR KR1019940703355A patent/KR100270134B1/ko not_active IP Right Cessation
- 1993-03-24 SK SK1152-94A patent/SK280160B6/sk not_active IP Right Cessation
- 1993-03-24 DE DE69306940T patent/DE69306940T3/de not_active Expired - Lifetime
- 1993-03-24 DK DK93906601T patent/DK0633784T4/da active
- 1993-03-24 WO PCT/EP1993/000712 patent/WO1993019780A1/en active IP Right Grant
- 1993-03-24 CA CA002132833A patent/CA2132833C/en not_active Expired - Lifetime
- 1993-03-24 HU HU9402758A patent/HU221253B1/hu unknown
- 1993-03-24 CZ CZ942355A patent/CZ283424B6/cs not_active IP Right Cessation
- 1993-03-25 IL IL10516193A patent/IL105161A/en not_active IP Right Cessation
- 1993-03-25 AP APAP/P/1993/000502A patent/AP570A/en active
- 1993-03-26 CN CN93105232A patent/CN1072963C/zh not_active Expired - Lifetime
- 1993-03-26 SI SI9300149A patent/SI9300149B/sl unknown
- 1993-06-08 SA SA93130573A patent/SA93130573B1/ar unknown
-
1994
- 1994-09-26 FI FI944442A patent/FI110843B/fi not_active IP Right Cessation
- 1994-09-26 NO NO943571A patent/NO309458B1/no not_active IP Right Cessation
-
1996
- 1996-09-05 AU AU64457/96A patent/AU6445796A/en not_active Abandoned
- 1996-12-30 GR GR960403615T patent/GR3022174T3/el unknown
-
1998
- 1998-03-19 HK HK98102341A patent/HK1003218A1/xx unknown
-
1999
- 1999-06-10 AU AU33974/99A patent/AU3397499A/en not_active Abandoned
-
2002
- 2002-01-02 AU AU10008/02A patent/AU767755B2/en not_active Expired
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO309458B1 (no) | Hepatitisvaksiner som inneholder 3-O-deacylert monofosforyl- lipid A og anvendelse derav | |
| AP515A (en) | "Vaccine compositions". | |
| US5972346A (en) | Hepatitis B vaccine | |
| US6893644B2 (en) | Hepatitis vaccines containing 3-O-deacylated monophoshoryl lipid A | |
| US20020192224A1 (en) | Hepatitis b vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |